PPARγ agonists (e.g., TZDs) have been shown to induce apoptosis in various cancer cells including lymphoma, multiple myeloma, bladder, gastric, esophageal, pancreatic, hepatoma, colon, breast, brain, and lung cancer cells [21]. This evidence concerns the gene PPARG and cancer.